{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:38:14Z","timestamp":1792636694711,"version":"4.5.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Topiramate is traditionally described as causing a hyperchloremic, non-anion gap metabolic acidosis due to carbonic anhydrase inhibition. However, the underlying physicochemical mechanisms have never been systematically reassessed using the Stewart approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review of all published cases and re-evaluated the available biochemical data using the Stewart physicochemical model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 38 identified patients, only seven had sufficient information for full or near-complete strong ion analysis. In every patient with genuine metabolic acidosis, the strong ion gap was elevated, suggesting an excess of unmeasured anions that was not detected by the conventional anion gap. Hyperchloremia, although common, was inconsistently present, and chloride physiology was frequently misclassified. Several patients had normal pH or normal bicarbonate despite significant physicochemical abnormalities, reflecting mixed disorders involving respiratory alkalosis and weak-acid effects. An illustrative case reproduced this pattern, with a high-strong ion gap and normal anion gap masked by hypocapnia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings suggest that topiramate-induced metabolic acidosis is physiologically heterogeneous and often concealed within the Henderson\u2013Hasselbalch framework. Strong ion analysis provides a more complete description of the underlying mechanism and reveals unmeasured anions as a major and previously unrecognized contributor to this drug's metabolic effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/joneph\/aajag158","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:42:44Z","timestamp":1780573364000},"page":"1353-1362","source":"Crossref","is-referenced-by-count":0,"title":["Reappraisal of topiramate-associated metabolic acidosis: a systematic review using physicochemical acid\u2013base analysis"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9677-4451","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Franconieri","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Centre Hospitalier du Forez , Montbrison ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00ebl","family":"Sagbohan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre Hospitalier du Forez , Montbrison ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"Oehler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Infectious Diseases, Centre Hospitalier de Polyn\u00e9sie Fran\u00e7aise , Pape'ete, Tahiti ,","place":["French Polynesia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"2026102121381444400_aajag158-B1","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1517\/14740338.2014.934669","article-title":"Safety of topiramate for treating migraines","volume":"13","author":"Marmura","year":"2014","journal-title":"Expert Opin Drug Saf."},{"key":"2026102121381444400_aajag158-B2","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/BF01997718","article-title":"Efficacy and safety of topiramate in refractory epilepsy: a long-term prospective trial","volume":"17","author":"Tartara","year":"1996","journal-title":"Ital J Neurol Sci."},{"key":"2026102121381444400_aajag158-B3","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.yebeh.2004.03.002","article-title":"Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center","volume":"5","author":"Bootsma","year":"2004","journal-title":"Epilepsy Behav."},{"key":"2026102121381444400_aajag158-B4","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1177\/0300060516669897","article-title":"The frequency and severity of metabolic acidosis related to topiramate","volume":"44","author":"T\u00fcre","year":"2016","journal-title":"J Int Med Res"},{"key":"2026102121381444400_aajag158-B5","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1139\/y83-207","article-title":"Modern quantitative acid\u2013base chemistry","volume":"61","author":"Stewart","year":"1983","journal-title":"Can J Physiol Pharmacol."},{"key":"2026102121381444400_aajag158-B6","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1097\/01.CCM.0000286399.21008.64","article-title":"Disorders of acid-base balance","volume":"35","author":"Kellum","year":"2007","journal-title":"Crit Care Med."},{"key":"2026102121381444400_aajag158-B7","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026102121381444400_aajag158-B8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.4103\/0971-4065.177136","article-title":"Mixed acid-base disorder secondary to topiramate use in traumatic brain injury","volume":"26","author":"Golla","year":"2016","journal-title":"Indian J Nephrol."},{"key":"2026102121381444400_aajag158-B9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1080\/21548331.2017.1370969","article-title":"Topiramate and metabolic acidosis: an evolving story","volume":"45","author":"Gupta","year":"2017","journal-title":"Hosp Pract."},{"key":"2026102121381444400_aajag158-B10","doi-asserted-by":"publisher","first-page":"404","DOI":"10.11613\/BM.2017.042","article-title":"Topiramate induced metabolic acidosis and kidney stones \u2013 a case study","volume":"27","author":"Salek","year":"2017","journal-title":"Biochem Med (Zagreb)."},{"key":"2026102121381444400_aajag158-B11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/ccr3.2733","article-title":"Topiramate causing type II renal tubular acidosis: a case and review of the mechanism","volume":"8","author":"Chahin","year":"2020","journal-title":"Clin Case Rep."},{"key":"2026102121381444400_aajag158-B12","doi-asserted-by":"publisher","first-page":"e772","DOI":"10.1097\/MJT.0000000000000781","article-title":"Topiramate-associated renal tubular acidosis","volume":"25","author":"Parthvi","year":"2018","journal-title":"Am J Ther."},{"key":"2026102121381444400_aajag158-B13","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1590\/S0004-282X2005000300032","article-title":"Topiramate and severe metabolic acidosis: case report","volume":"63","author":"Burmeister","year":"2005","journal-title":"Arq Neuropsiquiatr."},{"key":"2026102121381444400_aajag158-B14","doi-asserted-by":"publisher","first-page":"213.e1-","DOI":"10.1016\/j.genhosppsych.2012.04.008","article-title":"Hallucinations and comorbid renal tubular acidosis caused by topiramate in a patient with psychiatric history","volume":"35","author":"Cheng","year":"2013","journal-title":"Gen Hosp Psychiatry."},{"key":"2026102121381444400_aajag158-B15","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1111\/j.1526-4610.2007.00921.x","article-title":"Migraine and topiramate induced dyspnea","volume":"47","author":"Delpirou-Nouh","year":"2007","journal-title":"Headache"},{"key":"2026102121381444400_aajag158-B16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1460-9592.2005.01415.x","article-title":"Topiramate and metabolic acidosis: a case series and review of the literature","volume":"15","author":"Groeper","year":"2005","journal-title":"Paediatr Anaesth."},{"key":"2026102121381444400_aajag158-B17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.amjmed.2003.08.021","article-title":"Topiramate-induced renal tubular acidosis","volume":"116","author":"Izzedine","year":"2004","journal-title":"Am J Med."},{"key":"2026102121381444400_aajag158-B18","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1017\/s0012162201001268","article-title":"Topiramate-induced metabolic acidosis: report of two cases","volume":"43","author":"Ko","year":"2001","journal-title":"Dev Med Child Neurol"},{"key":"2026102121381444400_aajag158-B19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0887-8994(99)00143-5","article-title":"Central hyperventilation related to administration of topiramate","volume":"22","author":"Laskey","year":"2000","journal-title":"Pediatr Neurol."},{"key":"2026102121381444400_aajag158-B20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.5863\/1551-6776-8.4.287","article-title":"Metabolic acidosis in a pediatric patient receiving topiramate","volume":"8","author":"Malik","year":"2003","journal-title":"J Pediatr Pharmacol Ther."},{"key":"2026102121381444400_aajag158-B21","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.2146\/ajhp070395","article-title":"Hyperchloremic, normal anion-gap, metabolic acidosis due to topiramate","volume":"65","author":"Mathews","year":"2008","journal-title":"Am J Health Syst Pharm."},{"key":"2026102121381444400_aajag158-B22","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1345\/aph.1K508","article-title":"Hyperventilation and cerebrospinal fluid acidosis caused by topiramate","volume":"42","author":"Montcriol","year":"2008","journal-title":"Ann Pharmacother"},{"key":"2026102121381444400_aajag158-B23","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/j.1365-2044.2004.03884.x","article-title":"Topiramate induced metabolic acidosis","volume":"59","author":"Ozer","year":"2004","journal-title":"Anaesthesia"},{"key":"2026102121381444400_aajag158-B24","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1093\/ndt\/gfl251","article-title":"Topiramate induces type 3 renal tubular acidosis by inhibiting renal carbonic anhydrase","volume":"21","author":"Sacr\u00e9","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"2026102121381444400_aajag158-B25","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jemermed.2008.11.017","article-title":"Severe non-anion gap metabolic acidosis induced by topiramate: a case report","volume":"38","author":"Shiber","year":"2010","journal-title":"J Emerg Med."},{"key":"2026102121381444400_aajag158-B26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1592\/phco.20.1.105.34662","article-title":"Acute mental status changes and hyperchloremic metabolic acidosis with long-term topiramate therapy","volume":"20","author":"Stowe","year":"2000","journal-title":"Pharmacotherapy"},{"key":"2026102121381444400_aajag158-B27","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1310\/hpj5004-264","article-title":"Methemoglobinemia caused by topical dapsone gel; renal tubular acidosis after topiramate administration; diabetic ketoacidosis following epidural steroid injection in a nondiabetic patient; galactorrhea associated with bupropion therapy; telaprevir-induced acquired perforating dermatosis; manic episodes associated with tramadol use","volume":"50","author":"Mancano","year":"2015","journal-title":"Hosp Pharm."},{"key":"2026102121381444400_aajag158-B28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.5863\/1551-6776-18.2.128","article-title":"Valproic acid and topiramate induced hyperammonemic encephalopathy in a patient with normal serum carnitine","volume":"18","author":"Blackford","year":"2013","journal-title":"J Pediatr Pharmacol Ther."},{"key":"2026102121381444400_aajag158-B29","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.39127","article-title":"Topiramate-induced coma in a 39-year-old female patient: burst suppression on EEG","volume":"15","author":"Hakoun","year":"2023","journal-title":"Cureus"},{"key":"2026102121381444400_aajag158-B30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s13181-010-0065-y","article-title":"Clinical effects and toxicokinetic evaluation following massive topiramate ingestion","volume":"6","author":"Lynch","year":"2010","journal-title":"J Med Toxicol."},{"key":"2026102121381444400_aajag158-B31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.4103\/JPN.JPN_86_17","article-title":"Early post-operative hemodynamic perturbation associated with topiramate-induced metabolic acidosis: a case report","volume":"13","author":"Singh","year":"2018","journal-title":"J Pediatr Neurosci."},{"key":"2026102121381444400_aajag158-B32","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.toxrep.2022.08.004","article-title":"Topiramate intoxications & hemodialysis \u2013 literature review and the first case report of a massive suicidal intoxication treated with hemodialysis","volume":"9","author":"Schutte","year":"2022","journal-title":"Toxicol Rep."},{"key":"2026102121381444400_aajag158-B33","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-245870","article-title":"Topiramate-induced severe electrolyte abnormalities and hypernatremia leading to central pontine myelinolysis","volume":"14","author":"Muaddi","year":"2021","journal-title":"BMJ Case Rep."},{"key":"2026102121381444400_aajag158-B34","doi-asserted-by":"publisher","first-page":"e606","DOI":"10.1097\/MJT.0000000000000447","article-title":"Chronic diarrhea and metabolic acidosis associated with topiramate use","volume":"24","author":"Gil","year":"2017","journal-title":"Am J Ther."},{"key":"2026102121381444400_aajag158-B35","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1006\/ebeh.2002.0339","article-title":"Topiramate overdose: clinical and laboratory features","volume":"3","author":"Fakhoury","year":"2002","journal-title":"Epilepsy Behav."},{"key":"2026102121381444400_aajag158-B36","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1213\/01.ANE.0000077694.55641.80","article-title":"Stewart approach is not always a practical clinical tool","volume":"98","author":"Effros","year":"2004","journal-title":"Anesth Analg."},{"key":"2026102121381444400_aajag158-B37","doi-asserted-by":"publisher","DOI":"10.1111\/apha.13667","article-title":"Strong ion difference: questionable stewardship","volume":"233","author":"Bie","year":"2021","journal-title":"Acta Physiol"},{"key":"2026102121381444400_aajag158-B38","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1213\/ANE.0000000000001261","article-title":"Stewart acid-base: a simplified bedside approach","volume":"123","author":"Story","year":"2016","journal-title":"Anesth Analg."},{"key":"2026102121381444400_aajag158-B39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4103\/jets.jets_1_24","article-title":"Quantification of metabolic acidosis at bedside by S.A.L.T approach","volume":"17","author":"Seshadri","year":"2024","journal-title":"J Emerg Trauma Shock."},{"key":"2026102121381444400_aajag158-B40","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1097\/ALN.0000000000004712","article-title":"Acid\u2013base analysis in the operating room: a bedside Stewart approach","volume":"139","author":"Story","year":"2023","journal-title":"Anesthesiology"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/7\/1353\/70676724\/aajag158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/7\/1353\/70676724\/aajag158.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:38:18Z","timestamp":1792633098000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/39\/7\/1353\/8763063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,8,18]]},"published-print":{"date-parts":[[2026,10,22]]}},"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajag158","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,18]]}}}